Zhang Yishi, He Wan, Zhan Ke, Zhang Luobin, Cao Hua, Xu Ruilian
Department of Oncology, Shenzhen People's Hospital, The Second Clinical Medical College of Jinan University, The First Affiliated Hospital of Southern University of Science and Technology, Shenzhen, China.
Department of Spine Surgery, Shenzhen People's Hospital, The Second Clinical Medical College of Jinan University, The First Affiliated Hospital of Southern University of Science and Technology, Shenzhen, China.
Front Oncol. 2023 May 16;13:1153233. doi: 10.3389/fonc.2023.1153233. eCollection 2023.
Malignant mesothelioma that originates from mediastinal (MMM) is a rare form of malignant pleural mesothelioma (MPM). The prognosis of advanced stage MPM was poor, and the traditional treatment was chemotherapy. Here, we present a patient with MMM that was treated with anlotinib, a multitargeted tyrosine kinase inhibitor (TKI) who had a 24-month progression-free survival (PFS). Further review of the literature showed that, despite some explorations of applying small-molecule multitargeted TKIs in the treatment of MPM, until today, no large series had a positive result. Anlotinib had been approved by the China Food and Drug Administration on treating non-small cell lung cancer, soft tissue sarcoma, renal cell carcinoma, and medullary thyroid cancer. We assumed that the ability of anlotinib to target more tyrosine kinase receptors than most of other TKIs could contribute to the long duration of PFS in this case, but further study is needed to further validate the efficacy of anlotinib in treatment of MPM.
起源于纵隔的恶性间皮瘤（MMM）是恶性胸膜间皮瘤（MPM）的一种罕见形式。晚期MPM的预后较差，传统治疗方法是化疗。在此，我们报告1例接受多靶点酪氨酸激酶抑制剂（TKI）安罗替尼治疗的MMM患者，其无进展生存期（PFS）达24个月。进一步查阅文献发现，尽管已对小分子多靶点TKI治疗MPM进行了一些探索，但截至目前，尚无大型系列研究取得阳性结果。安罗替尼已获中国食品药品监督管理总局批准用于治疗非小细胞肺癌、软组织肉瘤、肾细胞癌和甲状腺髓样癌。我们推测，安罗替尼能够靶向更多酪氨酸激酶受体，这可能是该病例PFS持续时间长的原因，但仍需进一步研究以进一步验证安罗替尼治疗MPM的疗效。
Zotero 插件
